Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $15.75.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Leerink Swann restated an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $16.00 price objective on shares of Kura Oncology in a research report on Tuesday, July 4th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/06/kura-oncology-inc-kura-receives-14-15-consensus-price-target-from-analysts.html.

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. State of Wisconsin Investment Board purchased a new stake in Kura Oncology in the second quarter valued at approximately $102,000. Oppenheimer & Co. Inc. raised its stake in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after purchasing an additional 1,600 shares in the last quarter. Segantii Capital Management Ltd purchased a new stake in Kura Oncology in the first quarter valued at approximately $120,000. Rhumbline Advisers purchased a new stake in Kura Oncology in the second quarter valued at approximately $131,000. Finally, Nationwide Fund Advisors purchased a new stake in Kura Oncology in the first quarter valued at approximately $136,000. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Shares of Kura Oncology (NASDAQ KURA) traded down 6.08% during mid-day trading on Friday, reaching $6.95. 134,569 shares of the company’s stock traded hands. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $12.10. The company’s market cap is $138.92 million. The firm has a 50-day moving average of $8.06 and a 200 day moving average of $8.71.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Equities analysts forecast that Kura Oncology will post ($1.60) EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.